Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 186

Sort by

Sort Order Select

Journal Articles

Impact of Socioeconomic Disparities on Outcomes in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia

Daniel J Olivieri, Megan Othus, Corentin Orvain, Eduardo Rodríguez-Arbolí, Filippo Milano, Brenda M. Sandmaier, Irum Khan, Chris Davis, Ryan S. Basom, Frederick R. Appelbaum, Roland B. Walter

Blood (2023) 142 (Supplement 1): 3809.

https://doi.org/10.1182/blood-2023-181244

Published: 2023

Journal Articles

131 I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML

Blood (2023) 142 (Supplement 1): 469.

https://doi.org/10.1182/blood-2023-182177

Published: 2023

Journal Articles

131 I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

Blood (2023) 142 (Supplement 1): 2159.

https://doi.org/10.1182/blood-2023-187433

Published: 2023

Journal Articles

BCMA-Directed Low Dose Alpha-Emitter Therapy Eliminates Minimal Residual Disease in a Multiple Myeloma Mouse Xenograft Model

Melissa L Comstock, Shyril O'Steen, Yukang Lin, Donald Hamlin, D Scott Wilbur, Johnnie J. Orozco, Rainer F. Storb, Roland B. Walter, Pinar Ataca Atilla, Brian G Till, Geoffrey R Hill, Brenda M. Sandmaier, Damian J Green

Blood (2023) 142 (Supplement 1): 53.

https://doi.org/10.1182/blood-2023-188055

Published: 2023

Journal Articles

High-Dose Targeted Radiation with 131 I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

Blood (2023) 142 (Supplement 1): 3529.

https://doi.org/10.1182/blood-2023-189040

Published: 2023

Journal Articles

Role of Measurable Residual Disease (MRD) Testing for the Prediction of Late Relapses Following Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia

Naveed Ali, Othus Megan, Eduardo Rodríguez-Arbolí, Corentin Orvain, Filippo Milano, Brenda M. Sandmaier, Chris Davis, Ryan S. Basom, Frederick R. Appelbaum, Roland B. Walter

Blood (2023) 142 (Supplement 1): 4308.

https://doi.org/10.1182/blood-2023-183117

Published: 2023

Journal Articles

Relative Prognostic Value of Flow Cytometric Measurable Residual Disease before Allogeneic Hematopoietic Cell Transplantation for Adults with MDS/AML or AML

Corentin Orvain, Naveed Ali, Megan Othus, Eduardo Rodríguez-Arbolí, Filippo Milano, Brenda M. Sandmaier, Bart L. Scott, Frederick R. Appelbaum, Roland B. Walter

Blood (2023) 142 (Supplement 1): 4315.

https://doi.org/10.1182/blood-2023-188633

Published: 2023

Journal Articles

An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML

Blood (2023) 141 (3): 295–308.

https://doi.org/10.1182/blood.2022016916

Published: 2023

Includes: Supplemental data

Journal Articles

Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML

Gabrielle Paras, Linde M. Morsink, Megan Othus, Filippo Milano, Brenda M. Sandmaier, Lucas C. Zarling, Raffaele Palmieri, Gary Schoch, Chris Davis, Marie Bleakley, Mary E. D. Flowers, H. Joachim Deeg, Frederick R. Appelbaum, Rainer Storb, Roland B. Walter

Blood (2022) 139 (11): 1694–1706.

https://doi.org/10.1182/blood.2021014804

Published: 2022

Includes: Supplemental data

Journal Articles

Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia

Blood (2021) 138 (5): 387–400.

https://doi.org/10.1182/blood.2020008812

Published: 2021

Includes: Supplemental data

Journal Articles

Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen–mismatched donors

Brian Kornblit, Barry E. Storer, Niels S. Andersen, Michael B. Maris, Thomas R. Chauncey, Effie W. Petersdorf, Ann E. Woolfrey, Mary E. D. Flowers, Rainer Storb, David G. Maloney, Brenda M. Sandmaier

Blood (2020) 136 (13): 1499–1506.

https://doi.org/10.1182/blood.2020005338

Published: 2020

Includes: Supplemental data

Journal Articles

Comparative Analysis of Total Body Irradiation (TBI)-Based and Non-TBI-Based Myeloablative Conditioning for Acute Myeloid Leukemia in Remission with and without Measurable Residual Disease

Evandro D. Bezerra, MD, Linde M Morsink, MD, Megan Othus, PhD, Brent L Wood, MD PhD, Min Fang, MD PhD, Brenda M Sandmaier, MD, Marco Last Mielcarek, MD, H. Joachim Deeg, MD, H Gary Schoch, Frederick R. Appelbaum, MD, Roland B. Walter, MD PhD MS

Blood (2019) 134 (Supplement_1): 321.

https://doi.org/10.1182/blood-2019-126364

Published: 2019

Journal Articles

Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young Adults with Ph-Negative Acute Lymphoblastic Leukemia in First Complete Remission: Comparison of CALGB 10403 to Patients Reported to the CIBMTR

Matthew J. Wieduwilt, MD PhD, Wendy Stock, MD, Anjali S. Advani, MD, Selina M. Luger, MD FRCPC, Richard A. Larson, MD, Martin S. Tallman, MD, Frederick R. Appelbaum, MD, Mei-Jie Zhang, Khalid Bo-Subait, Brenda M. Sandmaier, MD, Marcos de Lima, MD, Partow Kebriaei, MD, Mark Litzow, MD, Wael Saber, MD MS, Daniel J. Weisdorf, MD

Blood (2019) 134 (Supplement_1): 261.

https://doi.org/10.1182/blood-2019-128560

Published: 2019

Journal Articles

Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) As Graft-Vs-Host Disease (GVHD) Prophylaxis after Nonmyeloablative (NMA) Hematopoietic Cell Transplantation (HCT) Using HLA Class I or Class II Antigen Mismatched Donors: Results from a Phase II Multi-Center Trial

Brian Kornblit, MD PhD, Barry Storer, Michael B. Maris, MD, Niels Smedegaard Andersen, MD PhD, Thomas R. Chauncey, MD PhD, Effie W. Petersdorf, MD, Ann Woolfrey, MD, David G. Maloney, MD PhD, Rainer Storb, MD, Brenda M Sandmaier, MD

Blood (2019) 134 (Supplement_1): 369.

https://doi.org/10.1182/blood-2019-123196

Published: 2019

Journal Articles

Impact of Depth of Pretransplant Clinical Response on Outcomes of Acute Myeloid Leukemia Patients in First Complete Remission (AML-CR1) Who Undergo Allogeneic Hematopoietic Cell Transplantation (AlloHCT)

Mary-Elizabeth M. Percival, MD, Hai-Lin Wang, MPH, Mei-Jie Zhang, PhD, Elihu H. Estey, MD, Mark Litzow, MD, Partow Kebriaei, MD, Marcos de Lima, MD, Wael Saber, MD MS, Daniel J. Weisdorf, MD, Brenda M Sandmaier, MD

Blood (2019) 134 (Supplement_1): 4585.

https://doi.org/10.1182/blood-2019-123510

Published: 2019

Journal Articles

Myeloablative Conditioning Is Preferred for Allogeneic Transplantation of Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate but Not High Disease Risk Index

Nelli Bejanyan, MD, Mei-Jie Zhang, PhD, Khalid Bo-Subait, Hai-Lin Wang, MPH, Erica D. Warlick, MD, Claudio G Brunstein, MD PhD, Brenda M Sandmaier, MD, Mark Litzow, MD, Partow Kebriaei, MD, Wael Saber, MD MS, Daniel J. Weisdorf, MD

Blood (2019) 134 (Supplement_1): 4603.

https://doi.org/10.1182/blood-2019-123513

Published: 2019

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for Therapy-Related Myelodysplastic Syndromes and Acute Myeloid Leukemia

Leland Metheny, III, MD, Wael Saber, MD MS, Daniel J. Weisdorf, MD, Marcos de Lima, MD, Natalie Scott Callander, MD, Mark Litzow, MD, Partow Kebriaei, MD, Aric C. Hall, MD, Brenda M Sandmaier, MD, Mei-Jie Zhang, Hai-Lin Wang, MPH, Khalid Bo-Subait

Blood (2019) 134 (Supplement_1): 2036.

https://doi.org/10.1182/blood-2019-125946

Published: 2019

Journal Articles

The α-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model

Shyril O’Steen, Melissa L. Comstock, Johnnie J. Orozco, Donald K. Hamlin, D. Scott Wilbur, Jon C. Jones, Aimee Kenoyer, Margaret E. Nartea, Yukang Lin, Brian W. Miller, Theodore A. Gooley, Sherilyn A. Tuazon, Brian G. Till, Ajay K. Gopal, Brenda M. Sandmaier, Oliver W. Press, Damian J. Green

Blood (2019) 134 (15): 1247–1256.

https://doi.org/10.1182/blood.2019001250

Published: 2019

Includes: Supplemental data

Journal Articles

Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation

K. Scott Baker, Wendy M. Leisenring, Pamela J. Goodman, Ralph P. Ermoian, Mary E. Flowers, G. Schoch, Rainer Storb, Brenda M. Sandmaier, H. Joachim Deeg

Blood (2019) 133 (26): 2790–2799.

https://doi.org/10.1182/blood.2018874115

Published: 2019

Includes: Supplemental data

Journal Articles

Predictors of 90-Day Mortality after Admission to Intensive Care Unit (ICU) in Patients with Acute Myeloid Leukemia (AML): Application of a Novel, Recently Validated AML-Specific Risk Model

Ylinne Lynch, MD, Shirali Agarwal, MD, Matthew Modes, MD MPP, Matthew Triplette, MD MPH, Masumi Ueda, MD, Barry E. Storer, PhD, Mary-Elizabeth M. Percival, MD MS, Pamela S. Becker, MD, Brenda M. Sandmaier, MD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD, Mohamed L. Sorror, MD MSc

Blood (2018) 132 (Supplement 1): 3986.

https://doi.org/10.1182/blood-2018-99-115419

Published: 2018

NARROW

Impact of Socioeconomic Disparities on Outcomes in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia

131 I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML

131 I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

BCMA-Directed Low Dose Alpha-Emitter Therapy Eliminates Minimal Residual Disease in a Multiple Myeloma Mouse Xenograft Model

High-Dose Targeted Radiation with 131 I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

Role of Measurable Residual Disease (MRD) Testing for the Prediction of Late Relapses Following Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia

Relative Prognostic Value of Flow Cytometric Measurable Residual Disease before Allogeneic Hematopoietic Cell Transplantation for Adults with MDS/AML or AML

An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML

Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML

Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia

Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen–mismatched donors

Comparative Analysis of Total Body Irradiation (TBI)-Based and Non-TBI-Based Myeloablative Conditioning for Acute Myeloid Leukemia in Remission with and without Measurable Residual Disease

Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) As Graft-Vs-Host Disease (GVHD) Prophylaxis after Nonmyeloablative (NMA) Hematopoietic Cell Transplantation (HCT) Using HLA Class I or Class II Antigen Mismatched Donors: Results from a Phase II Multi-Center Trial

Impact of Depth of Pretransplant Clinical Response on Outcomes of Acute Myeloid Leukemia Patients in First Complete Remission (AML-CR1) Who Undergo Allogeneic Hematopoietic Cell Transplantation (AlloHCT)

Myeloablative Conditioning Is Preferred for Allogeneic Transplantation of Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate but Not High Disease Risk Index

Allogeneic Hematopoietic Stem Cell Transplantation for Therapy-Related Myelodysplastic Syndromes and Acute Myeloid Leukemia

The α-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model

Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation

Predictors of 90-Day Mortality after Admission to Intensive Care Unit (ICU) in Patients with Acute Myeloid Leukemia (AML): Application of a Novel, Recently Validated AML-Specific Risk Model

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only